The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study will initially include two substudies, and more substudies may be added as they become available.

This new study will check how safe and helpful a potential anticancer drug called BGB-16673 is in participants with R/R B-cell malignancies when it is given in combination with other medicines – sonrotoclax in substudy 1, and with zanubrutinib in substudy 2.

Key Inclusion Criteria:

• Must sign the informed consent form (ICF) and be capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the ICF
• Confirmed diagnosis of a R/R B-cell malignancy
• Protocol-defined measurable disease
• Stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
• Adequate organ function
• Female participants of childbearing potential must be willing to use a highly effective method of birth control and refrain from egg donation for the duration of the study and for 30 days after the last dose of BGB-16673 or zanubrutinib, or 90 days after the last dose of sonrotoclax. A negative urine or serum pregnancy test result must be provided 10-14 days before the first dose of study treatment
• Nonsterile male participants must be willing to use a highly effective method of birth control and refrain from sperm donation for the duration of the study and for 30 days after the last dose of BGB-16673 or zanubrutinib, or 90 days after the last dose of sonrotoclax
• Substudy 2 Inclusion Criteria:
  • Bruton tyrosine kinase (BTK) inhibitor-naive, or
  • Previously received treatment with a covalent BTK inhibitor and discontinued for reasons other than clinical progression

Key Exclusion Criteria:

• Treatment-naive B-cell malignancies
• Unable to comply with the requirements of the protocol
• Active leptomeningeal disease or uncontrolled, untreated brain metastasis
• Any malignancy ≤ 2 years before first dose of study treatment except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively
• Autologous stem cell transplant ≤ 3 months prior to screening or chimeric antigen T-cell therapy ≤ 3 months prior to screening
• Prior allogeneic stem cell transplant with active graft-versus-host disease (GVHD), or requiring immunosuppressive drugs for treatment of GVHD, or have taken calcineurin inhibitors within 4 weeks prior to consent
• Participants who have a history of severe allergic reactions or hypersensitivity to the active ingredient and excipients of BGB-16673, sonrotoclax, or zanubrutinib
• Substudy 1 Exclusion Criterion:
  • Prior treatment with a B-cell lymphoma-2 (Bcl-2) inhibitor
• Substudy 2 Exclusion Criterion:
  • Participants who discontinued prior zanubrutinib treatment due to intolerance

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Linear Clinical Research, Perth, Western Australia, 6009
Contact  +61 08 6382 5100
cancertrialshaem4@linear.org.au

Dr. Katharine Lewis

BeiGene

Phase 1

Phase 2

BGB-16673-104

NCT06634589